Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LIG1 | P18858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545960 | 0.89 | GAA (0.40) | SMN1; SMN2PKMCA2CA12CA1 | |
| SCHEMBL331731 | 0.73 | PKM (0.49) | SMN1; SMN2PKMAOX1CA2CA4 | |
| SCHEMBL4948416 | 0.73 | MEN1 (0.53) | SMN1; SMN2PKMAOX1CA2CA4 | |
| SCHEMBL8652973 | 0.70 | PKM (0.46) | SMN1; SMN2PKMAOX1CA2CA4 | |
| SCHEMBL3468614 | 0.70 | TSHR (0.50) | SMN1; SMN2PKMCA2CA12CA1 | |
| SCHEMBL6546064 | 0.70 | RAB9A (0.44) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL26346922 | 0.70 | MEN1 (0.44) | SMN1; SMN2PKMIDH1MEN1KMT2A | |
| SCHEMBL29211568 | 0.70 | MEN1 (0.56) | SMN1; SMN2ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL11319680 | 0.69 | SMN1; SMN2 (0.45) | SMN1; SMN2PKMAOX1CA2CA4 | |
| SCHEMBL9940137 | 0.69 | PKM (0.45) | SMN1; SMN2PKMAOX1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379533-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | Leo Pharma A/S (DK) | 2004-01-14 | — | — | EP | disclosed |
| US-6605742-B2 | Rheumatic diseases; antiarthritic agents; antitumor agents | LEO PHARMA A/S (DK) | 2003-08-12 | — | — | US | disclosed |
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | US | disclosed |
| WO-2002083696-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | CMA1, MMP9, CPA1 | SMN1; SMN2 4648/4885PKM 4358/4885AOX1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.